Jonas Willmann, MD

🚨 just published @ESTRO_RT and @EORTC consensus on re-irradiation: definition, reporting, and clinical decision making doi.org/10.1016/S1470-… @TheLancetOncol #radonc A thread 🧵 👇 1/n

What happens to pts with resectable NSCLC who don’t make it to surgery after neoadjuvant chemo-immunotherapy?@JTOonline In this multicenter study (n=57), definitive RT is a valid alternative: 👉 1-year OS 81% 👉 mPFS 16.1 mo 👉 Pneumonitis 18% 🔬 pubmed.ncbi.nlm.nih.gov/41852936/

🆙 #ELCC26 @myESMO 🇩🇰 🔥Proffered Paper session 1 ☑️TOP study: Osimertinib +/- Chemo in EGFRm + TP53 mutation 🎯PFS HR 0.44 (95%CI 0.32-0.61), ORR 82.9% vs. 72.0% 🎙️Dr. Yunpeng Yang 🎙️Chair: @peters_solange 📍NCT04695925 @OncoAlert @Larvol #LCSM

Big implications, folks, for today's new reports on the thymus gland and healthspan —Our thymus gland largely involutes after the teenage years, but AI used to determine its persistent level of health —Healthy adult thymus linked to an array of remarkably improved health outcomes in 2 cohorts —Cardiovascular incidence and mortality reduced (Figure); also less all-cause mortality —Pulmonary mortality, digestive disease, metabolic disease mortality reduced (Figure) —Reduced inflammation; reduced lung cancer; improved metabolic markers nature.com/articles/s4158…

Big news: the thymus may be critical for adult health What if we missed something fundamental about the immune system? In two back-to-back papers in Nature, we show thymic health (AI on 30,000+ CT scans) links to longevity, disease risk & immunotherapy outcomes.

Radiation oncology is changing fast. But radiation can still injure normal tissue. An excellent review in @NEJM explains how modern RadOnc is reducing that risk: -Precision planning -Adaptive radiotherapy -Biologic personalization -AI-assisted treatment design the goal is simple: maximize tumor control while protecting normal tissue nejm.org/doi/full/10.10… @OncoAlert

Radiotherapy patterns and factors associated with pneumonitis in PACIF... sciencedirect.com/science/articl…

🆕Our Feb issue is live! 📉Articles: #NSCLC, #glioblastoma, #prostatecancer, #oesophagealcancer, #coloncancer 📰Reviews: International Multidisciplinary Consensus Group for Malignant Spinal Cord Compression + ReCOG consensus on multiple courses of RT thelancet.com/issue/S1470-20…

Hot off the presses, ReCOG consensus statement endorsed by multiple Rad Onc societies now in @TheLancetOncol. Major step forward for advancing reirradiation. Congrats to authors, in particular @DrKCParadis, @ChuckMayoPhD, @elizapowerpuff. @UMichRadOnc. sciencedirect.com/science/articl…

Extremely excited to share our latest article published @TheLancetOncol a few hours ago: authors.elsevier.com/a/1mYT65EIIgTS…. The WOLVERINE individual patient meta-analysis was an international collaboration and part of X-MET collaboration. Goal was to evaluate MDT in oligomet prostate ca.

The time of day for cancer immunotherapy is associated with major outcomes. Early is better. Results from a randomized trial of lung cancer, backs up the importance of our circadian rhythm and immune system nature.com/articles/s4159…

Outcomes for patients with stage III KRAS mutant NSCLC who receive chemoradiation @JTOonline. KRAS mt associated with worse PFS (16m vs 28m), higher distant metastases, higher brain metastases, particularly with CDKN2A or STK11 co-mt. jto.org/article/S1556-…

Explainable AI for global oncology policy 🔍🌍 Key takeaway: radiotherapy capacity + UHC expansion repeatedly emerge as high-impact drivers of cancer outcomes ‼️ Higher total health spending alone may be insufficient without strategic allocation. @militspatel @EChrisDee

📜 In @Annals_Oncology led by @MilitSPatel, we present, "Machine learning reveals country-specific drivers of global cancer outcomes" 🌍🌎🌏 @MSKCancerCenter @TataMemorial @AKUHNairobi @UZH_en @UTSW_RadOnc @umiamimedicine @harvardmed @MedicalCollege 🔗 sciencedirect.com/science/articl…

Results from NRG LU005 @JCO_ASCO - phase III trial of chemoradiation with or without concurrent then maintenance atezolizumab. No difference in survival (OS 31.1 vs 36.1m, HR 1.03) or PFS (12.1 vs 11.4m, HR 0.98). Main difference from ADRIATIC is timing, which is everything.

Excited to share our Phase 2 trial results in the @RedJournal, investigating the combination of SBRT and pembrolizumab for patients with recurrent, or metastatic HNSCC that was refractory to prior PD-1 inhibitor treatment. HNSCC patients progressing on PD-1 inhibitors have poor prognoses. While many systemic therapies are under investigation, our data suggests that comprehensive SBRT+pembrolizumab is an effective strategy for patients with oligoprogression. Key Findings with comprehensive SBRT+pembro to all progressing lesions (Cohort B): 3-Month PFS: 67% (median PFS 5.7 months) OS: Median OS was 10.1 months. Safety: The approach was feasible and safe, even in the re-irradiation setting. Results with comprehensive SBRT in Cohort B were more favorable to Cohort A where only a single lesion was irradiated+pembro. Consistent with other studies, we did not observe abscopal responses. Huge credit to Jonathan So for leading the correlative analyses. Higher baseline CD8+ central memory T cells were correlated with treatment benefit - a starting point for deeper analyses currently ongoing. Full article here: doi.org/10.1016/j.ijro… #HNSCC #RadOnc #Immunotherapy #SBRT Figure 2: Kaplan-Meier analysis demonstrating more favorable PFS and OS for Cohort B (blue, comprehensive SBRT).

@JAMANetworkOpen @EChrisDee @IyengarPuneeth @Mat_Guc @JordiRemon @HendriksLizza Congrats to the team from @USZ_CH @RadOncUSZ and collaborators worldwide 👏 @EChrisDee @Mat_Guc @IyengarPuneeth @HendriksLizza @JordiRemon @SahgalArjun @MayingerMayinger

@JAMANetworkOpen @EChrisDee @IyengarPuneeth @Mat_Guc @JordiRemon @HendriksLizza 🔁 Repeat SBRT: Many studies reported repeat SBRT for limited progression, enabling continued deferral of systemic therapy—suggesting a treatment strategy rather than a one-time intervention.

🚀 Can SBRT alone be used to treat oligometastatic cancer—allowing selected patients to defer systemic therapy? Our meta-analysis, now published in @JAMANetworkOpen, evaluates systemic therapy–free survival after SBRT without upfront systemic therapy.